• Image courtesy of Dr Kristen Brennand & Dr Fred H. Gage/ Salk Institute for Biological Studies

    human stem cells 2
  • Image courtesy of Dr Yichen Shi and Dr Rick Livesey/ Cambridge Stem Cell Institute

    human stem cells
About EUCelLEX

The European EUCelLEX Project consists in a full examination of the application of the European rules regarding cell banks together with current practices in respect of the therapeutic use of human cells in the different countries concerned. The purpose is to submit the data obtained to the European Commission for it to draw up legislative measures in line with medical advances in this field.
The EUCelLEX project has received funding from the European Union’s FP7 and is coordinated by Emmanuelle RIAL-SEBBAG (Inserm).

Home

News

EUCelLEX FINAL INTERNATIONAL CONFERENCE.
ENGAGING STAKEHOLDERS FOR RESPONSIBLE STEM CELLS RESEARCH

The EUcelLEX consortium is delighted to invite you at the EUCelLEX Final International Conference

to be held on September 22nd-23rd in Paris.

Alongside the conference, we are organising a joint workshop with the  EAHL, named

Stem cells banking, legal conditions and governance issues.

Preliminary programme, call for abstracts and online registration here !

Dates: 11-12 of May, 2016

Organizers: Sciences Po – CEVIPOF, CNRS, Inserm.
Venue: Paris.

Announcement

The EUcelLex project is thrilled to announce the workshop: «Stem cells in translation: the governance of clinical promise in regenerative medicine» to be held in Paris, on 11th and 12th May, 2016.
The objective of this workshop is to analyze governance issues at the translational frontier of stem cell science.

UPDATED Final programme here

WS attendance is free but requires registration. In case you are interested in participating, you should send a request to Madame Marcelle Bourbier: marcelle.bourbier@sciencespo.fr and/or to Maryline Auge: maryline.auge@sciencespo.fr

More information here

We invite you to save the revised date for our ELSI 2.0 and EUCelLEX Project Satellite Symposium at the 13th World Congress of Bioethics organised by the International Association of Bioethics (IAB) in Edinburgh on Tuesday 14 June 2016.

Abstract submission deadline : Friday 1st April 2016.

IMPORTANT : a limited number of bursaries will be available to subsidise junior researchers (from within and outside the EU) to participate.

More information here.

Authors: R. Isasi, E. Kleiderman, B. M. Knoppers.

Article in Science 22 Jan 2016. Vol. 351, Issue 6271, pp. 337-339. DOI: 10.1126/science.aad6778.

Balancing therapeutic prospects brought by scientific advances with regulation to address highly contested socioethical issues is the ultimate challenge in dealing with disruptive science. Human genome editing is a powerful tool that offers great scientific and therapeutic potential. Yet, it rejuvenates socioethical and policy questions surrounding the acceptability of germline modification (…)

 

Part of this work is supported by the EUCelLEX project.

Authors: John Gardner, Alex Faulkner, Aurélie Mahalatchimy & Andrew Webster.

Article in Regenerative Medicine, Vol. 10, No. 7, Pages 885-895 , DOI 10.2217/rme.15.50.

Abstract : There is concern that translation ‘from bench to bedside’ within regenerative medicine (RM) will fail to materialize, or will be dismally slow, due to various challenges arising from the highly novel and disruptive nature of RM. In this article, we provide a summary of these challenges, and we critically engage with the notion that such challenges are specific to RM. It is important, we argue, not to overstate the exceptional nature of RM, as valuable lessons can be learned from elsewhere in medicine. Using several examples of technology adoption, we suggest that emerging RM products and procedures will have to work hard to find or create an adoption space if translation into the clinic is to be successful.